Olema Prescribed drugs director sells shares price $147,955

SAN FRANCISCO—Harmon Cyrus, a director at Olema Prescribed drugs, Inc. (NASDAQ:OLMA), a $493.56 million market cap biotech firm, lately executed a sequence of inventory transactions, in response to a submitting with the Securities and Alternate Fee. The transactions come as InvestingPro knowledge reveals the inventory has skilled important volatility, falling 18% previously week. On December 9, Cyrus acquired 29,250 shares of frequent inventory with none financial trade, as these shares have been a part of a performance-based restricted inventory unit award that vested upon assembly particular firm milestones.

On December 10 and 11, Cyrus offered a complete of 16,393 shares of Olema Prescribed drugs inventory. These gross sales have been primarily performed to cowl tax obligations associated to the vesting of the performance-based inventory items. The transactions have been executed at costs starting from $8.66 to $9.39 per share, leading to a complete worth of roughly $147,955.

Following these transactions, Cyrus holds 764,140 shares immediately and an extra 122,028 shares not directly via the Harmon Household Traders LLC.

In different current information, Olema Prescribed drugs has been making notable strides with a number of important developments. H.C. Wainwright reaffirmed a Purchase score for Olema, following the presentation of preclinical knowledge for the corporate’s KAT6 inhibitor, OP-3136, on the EORTC-NCI-AACR Symposium. The info confirmed elevated inhibition of T47D breast most cancers cells when OP-3136 was mixed with different most cancers medicine, notably ribociclib.

The corporate additionally introduced promising knowledge from its Part 1b/2 examine of palazestrant mixed with ribociclib for treating ER+/HER2- metastatic breast most cancers. The examine, which has enrolled 62 sufferers, confirmed that palazestrant didn’t have an effect on ribociclib publicity, a major discovering as different oral Selective Estrogen Receptor Degraders (SERDs) have required dosage changes when used with CDK4/6 inhibitors.

TD Cowen reiterated a Purchase score, inspired by the Scientific Profit Charge of 78-79% from a Part II trial involving palbociclib and ribociclib. Jefferies additionally maintained a Purchase score, highlighting the potential of the corporate’s KAT6 inhibitor, OP-3136. The agency expects OP-3136 to enter Part 1 trials in early 2025.

Goldman Sachs maintained its Purchase score on Olema Prescribed drugs, following the presentation of preclinical knowledge for OP-3136 on the EORTC-NCI-AACR Symposium. The research demonstrated OP-3136’s anti-tumor exercise, exhibiting additional enchancment when used with endocrine remedy and CDK4/6 inhibitors. These are current developments shaping the investor sentiment round Olema Prescribed drugs.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.